Voriconazole 200mg/vial; lyophilized pwd for IV infusion after reconstitution and dilution; preservative-free. The primary mechanism of action of voriconazole is the inhibition of fungal cytochrome ...
Prague, Czech Republic, May 3, 2004 – Pfizer Inc's antifungal VFEND® (voriconazole) was shown to be as effective as a regimen of amphotericin B followed by fluconazole in the primary treatment of ...
Voriconazole 40mg/mL; pwd for reconstitution; orange flavor. Store at 2°C to 8°C (36°F to 46 F) in a refrigerator before reconstitution. The shelf-life is 24 months. The reconstituted suspension ...
NEW YORK, October 25, 2005 – A new analysis of treatment procedures for the potentially deadly fungal infection invasive aspergillosis suggests that making the right treatment decision as soon as ...
PITTSBURGH, Feb. 15, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Voriconazole Tablets, 50 mg and 200 mg, under a ...
PITTSBURGH — Mylan has launched a generic drug for fungal infections, the company said Tuesday. Mylan announced the launch, through subsidiary Mylan Pharmaceuticals, of voriconazole tablets in the ...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE:PFE) today reported the top-line results of an international Phase III clinical trial which compared the combination of VFEND ® (voriconazole) and ERAXIS ...
New Delhi, Dec 19: Homegrown pharma major Lupin Ltd today announced the launch of generic version of its voriconazole tablets and oral suspension used for treatment of fungal infections in children.
Jan. 13, 2005 — The U.S. Food and Drug Administration (FDA) has approved an expanded indication for tositumomab therapy, allowing its use in a broader population of patients with non-Hodgkin's ...
Le groupe pharmaceutique américain Pfizer a annoncé aujourd’hui qu’il venait de conclure un accord avec deux filiales du génériqueur Mylan concernant la commercialisation d’une version générique de ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced that it has entered into an agreement with two subsidiaries of Mylan Inc. relating to a generic version of Vfend® (voriconazole), an antifungal ...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE:PFE) today reported the top-line results of an international Phase III clinical trial which compared the combination of VFEND ® (voriconazole) and ERAXIS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results